Answers are grounded in this paper and cite their sources.
Literature review reveals extensive metabolic reprogramming driven by oncogenic MYC in human cancers, highlighting targetable metabolic dependencies for therapy.
Cancer cells must rewire cellular metabolism to satisfy the demands of unbridled growth and proliferation. As such, most human cancers differ from normal counterpart tissues by a plethora of energetic and metabolic reprogramming. Transcription factors of the MYC family are deregulated in up to 70% of all human cancers through a variety of mechanisms. Oncogenic levels of MYC regulates almost every aspect of cellular metabolism, a recently revisited hallmark of cancer development. Meanwhile, unrestrained growth in response to oncogenic MYC expression creates dependency on MYC-driven metabolic pathways, which in principle provides novel targets for development of effective cancer therapeutics. In the current review, we summarize the significant progress made toward understanding how MYC deregulation fuels metabolic rewiring in malignant transformation.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: